专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2010122980A8 NOVEL THYROID HORMONE ß RECEPTOR AGONIST 审中-公开
标题翻译：新型THYROID HORMONEß受体激动剂
公开(公告)号：WO2010122980A8
公开(公告)日：2011-02-17
申请号：PCT/JP2010056936
申请日：2010-04-19
申请人： MITSUBISHI TANABE PHARMA CORP , KAWATA SHINJI , MATSUMOTO KOJI , NIIJIMA MAKI , TAKAHASHI TAICHI
发明人： KAWATA SHINJI , MATSUMOTO KOJI , NIIJIMA MAKI , TAKAHASHI TAICHI
IPC分类号： C07D213/65 , A61K31/44 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P5/14 , A61P9/00 , A61P9/04 , A61P9/10 , A61P17/00 , A61P25/24 , A61P43/00 , C07D213/74 , C07D213/75 , C07D213/81 , C07D401/10 , C07D405/04 , C07D413/12 , C07D413/14
CPC分类号： C07D213/65 , A61K31/44 , A61K31/4418 , A61K31/443 , A61K31/4433 , A61K31/4439 , C07D213/74 , C07D213/75 , C07D213/81 , C07D401/10 , C07D405/04 , C07D413/12 , C07D413/14
摘要： Disclosed is a heterocyclic derivative which has a thyroid hormone ß receptor agonistic activity and is therefore effective for the prevention or treatment of diseases associated with the activity. Specifically disclosed are: a compound represented by general formula [I] (wherein each symbol is as defined in the description) or a pharmacologically acceptable salt thereof; and a pharmaceutical preparation comprising the compound as an active ingredient.
摘要翻译：公开了具有甲状腺激素ß受体激动活性的杂环衍生物，因此对于预防或治疗与该活性相关的疾病是有效的。具体公开的是：由通式[I]表示的化合物（其中每个符号如说明书中所定义）或其药理学上可接受的盐; 和包含该化合物作为活性成分的药物制剂。

22. 发明申请

WO2009156861A3 SUBSTITUTED PYRIMIDONE DERIVATIVES 审中-公开
标题翻译：取代的吡咯烷酮衍生物
公开(公告)号：WO2009156861A3
公开(公告)日：2010-04-01
申请号：PCT/IB2009006486
申请日：2009-06-25
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVENTIS , LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
IPC分类号： A61K31/519 , A61P25/00 , C07D471/04
CPC分类号： C07D471/04 , A61K31/519
摘要： Pyrimidone derivatives of formula (I) wherein: R1 represents a 4-pyridine ring; R2 represents a hydrogen atom; R3 represents a hydrogen atom; R4 represents : a hydrogen atom; a phenyl ring, this ring being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 halogenated alkoxy group, R5 represents a hydrogen atom, a C1-6 alkyl group, a 4-pyridine group, a phenyl group, these groups being optionally substituted, R6 represents a hydrogen atom, a C1-6 alkyl group, a benzyloxy group, a phenyl C1-6 alkyl group, these groups being optionally substituted, in form of a free base or of an addition salt with an acid. Use in therapeutic.
摘要翻译：式（I）的嘧啶酮衍生物其中：R1表示4-吡啶环; R2表示氢原子; R3表示氢原子; R4表示：氢原子; 苯环，该环任选被1至4个选自C 1-6烷基，卤素原子，C 1-2卤代烷基，羟基，C 1-6烷氧基，C 1-2 卤代烷氧基，R5表示氢原子，C1-6烷基，4-吡啶基，苯基，这些基团任意取代，R6表示氢原子，C1-6烷基，苄氧基，苯基C 1-6烷基，这些基团任选被取代，以游离碱的形式或与酸的加成盐形式。用于治疗。

23. 发明申请

WO2009156861A2 SUBSTITUTED PYRIMIDONE DERIVATIVES 审中-公开
标题翻译：取代的吡咯烷酮衍生物
公开(公告)号：WO2009156861A2
公开(公告)日：2009-12-30
申请号：PCT/IB2009006486
申请日：2009-06-25
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVENTIS , LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
发明人： LOCHEAD ALISTAIR , SAADY MOURAD , YAICHE PHILIPPE
IPC分类号： A61K31/519 , A61P25/00 , C07D471/04
CPC分类号： C07D471/04 , A61K31/519
摘要： Pyrimidone derivatives of formula (I) wherein: R1 represents a 4-pyridine ring; R2 represents a hydrogen atom; R3 represents a hydrogen atom; R4 represents : a hydrogen atom; a phenyl ring, this ring being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C1-2 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 halogenated alkoxy group, R5 represents a hydrogen atom, a C1-6 alkyl group, a 4-pyridine group, a phenyl group, these groups being optionally substituted, R6 represents a hydrogen atom, a C1-6 alkyl group, a benzyloxy group, a phenyl C1-6 alkyl group, these groups being optionally substituted, in form of a free base or of an addition salt with an acid. Use in therapeutic.
摘要翻译：式（I）的嘧啶酮衍生物其中：R1表示4-吡啶环; R2表示氢原子; R3表示氢原子; R4表示：氢原子; 苯环，该环任选被1至4个选自C 1-6烷基，卤素原子，C 1-2卤代烷基，羟基，C 1-6烷氧基，C 1-2 卤代烷氧基，R5表示氢原子，C1-6烷基，4-吡啶基，苯基，这些基团任意取代，R6表示氢原子，C1-6烷基，苄氧基，苯基C 1-6烷基，这些基团任选被取代，以游离碱的形式或与酸的加成盐形式。用于治疗。

24. 发明申请

WO2010043682A2 PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT 审中-公开
标题翻译：制备作为SGLT抑制剂的化合物的方法
公开(公告)号：WO2010043682A2
公开(公告)日：2010-04-22
申请号：PCT/EP2009063503
申请日：2009-10-15
申请人： JANSSEN PHARMACEUTICA NV , MITSUBISHI TANABE PHARMA CORP , FILLIERS WALTER FERDINAND MARI , BROECKX RUDY LAURENT MARIA , NIESTE PATRICK HUBERT J , HATSUDA MASANORI , YOSHINAGA MASAHIKO , YADA MITSUHIRO
发明人： FILLIERS WALTER FERDINAND MARIA , BROECKX RUDY LAURENT MARIA , NIESTE PATRICK HUBERT J , HATSUDA MASANORI , YOSHINAGA MASAHIKO , YADA MITSUHIRO
CPC分类号： C07D333/12 , C07D409/10 , C07H7/04 , C07H13/04
摘要： The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
摘要翻译：本发明涉及一种制备具有抑制活性的化合物的新方法，所述化合物对存在于肠或肾中的钠依赖性葡萄糖转运蛋白（SGLT）具有抑制活性。

25. 发明申请

WO2009156864A3 SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES 审中-公开
标题翻译：取代的烷基吡啶-4-酮衍生物
公开(公告)号：WO2009156864A3
公开(公告)日：2010-04-01
申请号：PCT/IB2009006568
申请日：2009-06-25
申请人： MITSUBISHI TANABE PHARMA CORP , SANOFI AVANTIS , FAYOL AUDE , LOCHEAD ALISTAIR , SAADY MOURAD , VACHE JULIEN , YAICHE PHILIPPE
发明人： FAYOL AUDE , LOCHEAD ALISTAIR , SAADY MOURAD , VACHE JULIEN , YAICHE PHILIPPE
IPC分类号： C07D471/04 , A61K31/519 , A61P25/00
CPC分类号： C07D471/04 , A61K31/517 , A61K31/519 , C07D487/04
摘要： A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof (I), wherein, X represents a methylene, NH, a nitrogen atom substituted by a C(O)-O- (C1-6-alkyl) group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R3 represents a C1-6 alkyl group optionally substituted, R4 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-6 alkyl group; m represents 1 to 2 when X is a methylene or m represents 2 when X is NH, a nitrogen atom substituted by a C(O)-O-(C1- 6-alkyl) group; in the form of a free base or of an addition salt with an acid. Use in therapeutic
摘要翻译：由式（I）表示的嘧啶酮衍生物或其盐或其溶剂合物或其水合物（I），其中X表示亚甲基，NH，被C（O）-O-（C1 -6-烷基）基团; R1表示2,3或4-吡啶环或2,4或5-嘧啶环，该环任选被C 1-6烷基，C 1-6烷氧基或卤素原子取代; R2表示氢原子，C1-6烷基或卤素原子; R 3表示任选取代的C 1-6烷基，R 4表示氢原子，卤素原子，羟基，C 1-6烷基; 当X为亚甲基时，m表示1〜2，X表示NH时，m表示2，C（O）-O-（C1-6 - 烷基）取代的氮原子。以游离碱的形式或与酸的加成盐形式。用于治疗

26. 发明申请

WO2008004698A3 PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST 审中-公开
标题翻译： PYRAZOLO [1,5-A]吡嗪类化合物作为CB1受体拮抗剂
公开(公告)号：WO2008004698A3
公开(公告)日：2008-03-20
申请号：PCT/JP2007063762
申请日：2007-07-04
申请人： MITSUBISHI TANABE PHARMA CORP , TANIMOTO KOICHI , OI MARIKO , TSUBOI YASUNORI , MORITANI YASUNORI
发明人： TANIMOTO KOICHI , OI MARIKO , TSUBOI YASUNORI , MORITANI YASUNORI
IPC分类号： C07D487/04 , A61K31/519 , A61P25/00
CPC分类号： C07D487/04
摘要： The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R 1 and R 2 are the same or different and each an optionally substituted aryl group etc, R 0 is hydrogen atom, an alkyl group etc, E is a group of the formula: -C(=O)- or -SO 2 -, R is a group of the following formula [i], [ii] or [iii] etc: Ring A is (a) a C 3-8 cycloalkyl group optionally fused to a benzene ring or (b) a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom etc, R 3 is an alkyl group optionally substituted by an alkylthio group, R 4 is hydrogen atom, an alkyl group etc, one of R A and R B is an alkyl group etc, and the other is hydrogen atom, an alkyl group etc, or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供具有下式[I]的具有CB1受体拮抗活性的吡唑并[1,5-a]嘧啶化合物：其中R 1和R 2， SUP>相同或不同，各自为任选取代的芳基等，R 0为氢原子，烷基等，E为下式基团-C（= O） - 或 -SO 2 - ，R是下式[i]，[ii]或[iii]等的基团：环A是（a）C 3-8 任选地与苯环稠合的环烷基或（b）苯环，Q是单键或亚甲基，环B是4-至7-元脂族杂环基，所述环状基团通过其环碳结合原子与相邻的氮原子，X是硫原子等，R 3是任选被烷硫基取代的烷基，R 4是氢原子，烷基等 R A和R B之一是烷基等，另一个是氢原子，烷基等或药物其可接受的盐。

27. 发明专利

ES2362877T3 COMPUESTOS DE IMIDAZOLIN-2-ONA. 未知
公开(公告)号：ES2362877T3
公开(公告)日：2011-07-14
申请号：ES04728708
申请日：2004-04-21
申请人： MITSUBISHI TANABE PHARMA CORP , MITSUBISHI TANABE PHARMA CORP
发明人： KUBO AKIRA , IMASHIRO RITSUO , OGASAWARA AKIHITO , NAKAJIMA TATSUO , NAKANE TETSU , MIYOSHI HIDETAKA
IPC分类号： C07D401/04 , A61K31/4439 , A61K31/506 , A61P3/10 , A61P7/02 , A61P9/10 , A61P19/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P37/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14
摘要： Un compuesto seleccionado entre los compuestos base libre de estructuras 399 a 478, o una de sus sales farmacéuticamente aceptables. 399 Etilo 1,1-Dioxotetrahidrotiofen-3-ilamino 400 Etilo trans-4-(Metilcarbamoil)ciclohexilamino 401 Etilo 1,5-Dimetil-5-hidroxihexilamino 402 Isopropilo 1,5-Dimetil-5-hidroxihexilamino 403 Etilo cis-4-Hidroxi-4-metilciclohexilamino 404 Isopropilo trans-4-Hidroxi-4-metilciclohexilamino 405 Isopropilo trans-4-(1-Hidroxi-1-metiletil)ciclohexilamino 406 Etilo trans-4-Hidroxi-4-metilciclohexilamino 407 Isopropilo cis-4-Hidroxi-4-metilciclohexilamino 408 Etilo trans-4-(1-Hidroxi-1-metiletil)ciclohexilamino 409 Etilo (S)-1,2-Dimetil-2-hidroxipropilamino 410 Isopropilo (S)-1,2-Dimetil-2-hidroxipropilamino 411 Etilo 1,3-Dimetil-3-hidroxibutilamino 412 Isopropilo 1,3-Dimetil-3-hidroxibutilamino 413 Isopropilo 2-Mercapto-2-metilpropilamino 414 Isopropilo 1,1-Bishidroximetilpropilamino 415 Isopropilo 2-Hidroxi-2-metilpropilamino 416 Etilo 4-Piperidilamino 417 1,2-Dimetil-2-hidroxipropilo Isopropilamino 418 1,2-Dimetil-2-hidroxipropilo cis-4-Hidroxi-4-metilciclohexilamino 419 1,2-Dimetil-2-hidroxipropilo (S)-1,2-Dimetil-2-hidroxipropilamino 420 1,2-Dimetil-2-hidroxipropilo Trans-4-Hidroxi-4-metilciclohexilamino 421 2-Hidroxi-1,1,2-trimetilpropilo Isopropilamino 422 2-Hidroxi-1,1,2-trimetilpropilo Trans-4-Hidroxi-4-metilciclohexilamino 423 3-Hidroxi-3-metilbutilo Isopropilamino 424 3-Hidroxi-3-metilbutilo 1,1-Dimetil-2-hidroxietilamino 425 3-Hidroxi-3-metilbutilo 2,2-Dimetil-3-hidroxipropilamino 426 3-Hidroxi-3-metilbutilo 1-Hidroximetilciclopentilamino 427 3-Hidroxi-3-metilbutilo trans-4-Hidroxi-4-metilciclohexilamino 428 3-Hidroxi-3-metilbutilo 4-Tetrahidropiranilamino 429 3-Hidroxi-3-metilbutilo (R)-1,2-Dimetil-2-hidroxipropilamino 430 3-Hidroxi-3-metilbutilo (S)-1,2-Dimetil-2-hidroxipropilamino 431 3-Hidroxi-3-metilbutilo trans-4-Hidroxiciclohexilamino 432 3-Hidroxi-3-metilbutilo 1-Metanosulfonilpiperidin-4-ilamino 433 3-Hidroxi-3-metilbutilo 1-Etanosulfonilpiperidin-4-ilamino 434 4-Tetrahidropiranilo Isobutilamino 435 4-Tetrahidropiranilo Isopropilamino 436 4-Tetrahidropiranilo trans-4-Hidroxi-4-metilciclohexilamino 437 4-Tetrahidropiranilo Ciclopropilamino 438 4-Tetrahidropiranilo 2,2-Dimetilpropilamino 439 1-Acetilpiperidin-4-ilo trans-4-Hidroxi-4-metilciclohexilamino 440 1-Acetilpiperidin-4-ilo 2,2-Dimetilpropilamino 441 1-Acetilpiperidin-4-ilo Isopropilamino 442 1-Acetilpiperidin-4-ilo Isobutilamino 443 1-Acetilpiperidin-4-ilo Ciclopropilamino 444 4-Tetrahidropiranil (R)-1,2-Dimetil-2-hidroxipropilamino 445 4-Tetrahidropiranil (S)-1,2-Dimetil-2-hidroxipropilamino 446 4-Tetrahidropiranilo (S)-2-Hidroxi-1-metiletilamino 447 4-Tetrahidropiranilo (S)-1-Hidroximetilpropilamino 448 4-Tetrahidropiranilo 1,1-Dimetil-2-hidroxietilamino 449 4-Tetrahidropiranilo 4-Tetrahidropiranilamino 450 1-Acetilpiperidin-4-ilo 1,1-Dimetil-2-hidroxietilamino 451 1-Acetilpiperidin-4-ilo 4-Tetrahidropiranilamino 452 1-Acetilpiperidin-4-ilo (S)-1-Hidroximetilpropilamino 453 1-Acetilpiperidin-4-ilo (S)-1,2-Dimetil-2-hidroxipropilamino 454 4-Tetrahidropiranilo trans-4-Hidroxiciclohexilamino 455 1-Acetilpiperidin-4-ilo trans-4-Hidroxiciclohexilamino 456 1-Metanosulfonilpiperidin-4-ilo trans-4-Hidroxiciclohexilamino 457 1-Metanosulfonilpiperidin-4-ilo trans-4-Hidroxi-4-metilciclohexilamino 458 1-Metanosulfonilpiperidin-4-ilo Isopropilamino 459 4-Tetrahidropiranilo 1-Metanosulfonilpiperidin-4-ilamino 460 1-Acetilpiperidin-4-ilo 1-Metanosulfonilpiperidin -4-ilamino 461 Isopropilo 1-Acetilpiperidin-4-ilamino 462 Isopropilo 1-Metanosulfonilpiperidin-4-ilamino 463 Isopropilo 1-(Isopropilosulfonil)piperidin-4-ilamino 464 Isopropilo 1-(Propilsulfonil)piperidin-4-ilamino 465 Isopropilo 1-(Butilsulfonil)piperidin-4-ilamino 466 Isopropilo 1-(Isobutiloxicarbonil)piperidin-4-ilamino 467 Isopropilo 1-butirilpiperidin-4-ilamino 468 Etilo 1-Acetilpiperidin-4-ilamino 469 Etilo 1-Metanosulfonilpiperidin-4-ilamino 470 Etilo 1-Etanosulfonilpiperidin-4-ilamino 471 Isopropilo 1-Etilcarbamoilpiperidin-4-ilamino 472 Isopropilo 1-Propilcarbamoilpiperidin-4-ilamino 473 Isopropilo 1-Isopropilcarbamoilpiperidin-4-ilamino 474 Isopropilo 1-Etanosulfonilpiperidin-4-ilamino 475 Isopropilo 1-Metoxicarbonilpiperidin-4-ilamino 476 Isopropilo 1-Etoxicarbonilpiperidin-4-ilamino 477 1-Metanosulfonilpiperidin-4-ilo Isopropilamino 478 1-Etanosulfonilpiperidin-4-ilo Isopropilamino

28. 发明公开

US20230355163A1 NEUROMUSCULAR DISEASE EVALUATION SYSTEM 审中-公开
公开(公告)号：US20230355163A1
公开(公告)日：2023-11-09
申请号：US18247015
申请日：2021-09-29
申请人： MITSUBISHI TANABE PHARMA CORP
发明人： Takeshi SAKATA , Akiko GOTO , Atsushi KATO , Manabu HIRAI
IPC分类号： A61B5/00 , A61B5/11
CPC分类号： A61B5/4082 , A61B5/1124 , A61B5/4842 , A61B5/112 , A61B5/1128
摘要： A neuromuscular disease evaluation device that is less invasive, highly sensitive, quantitative and objective, and capable of easily evaluating neuromuscular diseases. A device for evaluating motor functions related to neuromuscular diseases, comprising: a memory unit storing a reference value for evaluating a predetermined movement, which is calculated based on a position of at least one body part; an analysis unit for identifying a position of a body part of the user by analyzing information based on an image captured of the predetermined movement, including the user's body; and an evaluation unit for evaluating the motor function based on the numerical value calculated based on the position of the body part of the user and the reference value.

29. 发明公开

EP2933248A4 NOVEL RENIN INHIBITOR 有权转让
标题翻译：新型肾素抑制剂
公开(公告)号：EP2933248A4
公开(公告)日：2016-04-13
申请号：EP13836321
申请日：2013-09-13
申请人： MITSUBISHI TANABE PHARMA CORP , SHANGHAI PHARMACEUTICALS HOLDING CO LTD
发明人： IIJIMA TORU , TAKAHASHI YOICHI , HIRAI MIKI , SUGAMA HIROSHI , TOGASHI YUKO , SHEN JINGKANG , XIA GUANGXIN , WAN HUIXIN
IPC分类号： C07D265/30 , A61K31/5377 , A61P9/04 , A61P9/12 , A61P13/12 , A61P43/00 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/048
CPC分类号： C07D413/12 , C07D265/30 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048
摘要： The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R 1 is a cycloalkyl group or an alkyl, R 22 is an optionally substituted aryl and the like, R is a lower alkyl group, R 3 , R 4 , R 5 and R 6 are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl, or a pharmaceutically acceptable salt thereof.

30. 发明公开

EP2657230A4 AMIDE DERIVATIVE AND USE THEREOF 审中-公开
标题翻译：酰胺衍生物及其用途
公开(公告)号：EP2657230A4
公开(公告)日：2016-04-06
申请号：EP11832591
申请日：2011-10-13
申请人： MITSUBISHI TANABE PHARMA CORP
发明人： USHIO HIROYUKI , HAMADA MAIKO , WATANABE MASAYUKI , NUMATA ATSUSHI , FUJIE NAOTO , TAKASHIMA TOORU , FURUKAWA HIROYUKI , ANDO JUNKI
IPC分类号： C07D401/12 , A61K31/443 , A61K31/4439 , A61K31/4545 , A61K31/455 , A61K31/5377 , A61P19/02 , A61P29/00 , A61P37/02 , A61P43/00 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/12 , C07D495/04
CPC分类号： C07D405/14 , C07D401/12 , C07D401/14 , C07D405/12 , C07D417/12 , C07D495/04
摘要： The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式